Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year.

The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder appeared first on MedCity News.